treatment, months from androgen deprivation to CRPC, and PSA velocity.
INTRODUCTION AND OBJECTIVES:
Early detection of prostate cancer with PSA based screening can reduce the risk of prostate cancer mortality by 21%. Screening for prostate cancer has dramatically declined in the United States since the United States Preventive Services Task Force (USPSTF) recommended against routine PSA based prostate cancer screening for all men in 2012. This led to dramatic reductions in the diagnosis of localized disease across all clinical risk groups. We sought to study trends in newly diagnosed metastatic prostate cancer incidence, specifically the impact of patient age and race.
METHODS: We analyzed new prostate cancer incidence by stage at diagnosis between 1988-2014 using data from the California Cancer Registry. We further stratified cases by age and four major race/ethnicity groups (non-Hispanic white (NHW), non-Hispanic black (NHB), Hispanic and non-Hispanic Asian/PI (API)). Incidence rates per 100,000 were age-adjusted to the 2000 US Standard Population. Joinpoint regression was used to detect changes in incidence and to calculate the average percent change (APC) over time. Joinpoint finds the best fit model with the smallest number of joinpoints and will not add an additional joinpoint if it does not make significant improvement on the model. RESULTS: Adjusted rates of remote prostate cancer incidence for men of all races aged 65-74 and NHW men of all ages significantly increased over the most recent time period by 2.4% and 1%, respectively, p<0.05 (Figure 1 and 2) . In contrast, incidence of remote prostate cancer continued to decline for NHB (-2.42%), Hispanic (-1.94%), and API (-1.66%) men. Localized disease incidence continues to decline significantly for all age and racial groups.
CONCLUSIONS: Incidence rates of newly metastatic prostate cancer have significantly increased for the first time in California for men aged 65-74 and white men. Although not possible to determine the etiology of these findings, decreased PSA screening and early detection of aggressive as well as indolent tumors is likely to contribute. . 197, No. 4S, Supplement, Friday, May 12, 2017 The prognostic ability of PGG for multiple long term clinical endpoints was examined using Cox models. Interactions between PGG and race were tested. RESULTS: The cohort consisted of PGG 1 through 5, respectively: 2,077(48%), 1,171(27%), 521(12%), 409(10%), 147(3%). 1,596(38%) were African American. Median follow up was 86(IQR: 45 to 135) months. Higher PGG was associated with higher stage, older age, more recent year of surgery and surgical center (p<0.02). African American men had a lower PGG distribution (p¼0.028). Higher PGG was associated with increased risk of all clinical endpoints on univariable and multivariable regression including biochemical recurrence (BCR), adjuvant therapy, castrate resistant prostate cancer (CRPC) [ Figure 1 , left], metastases, prostate cancer specific mortality (PCSM) and overall survival (OS) [ Figure 1 , right] (all p<0.001).We found no significant interactions with race in predicting any of the measured outcomes. RESULTS: In the complete unadjusted dataset, an effect of increasing comorbidity was observed on PCa-specific and othercause mortality. Following adjustments for patient and tumour characteristics, the effect of comorbidity on PCa-specific mortality was lost, while maintained for other-cause mortality. Following additional adjustment for treatment type, an effect of comorbidity on PCaspecific mortality was not observed, while present for other-cause mortality.
CONCLUSIONS: During the study period in Sweden, comorbidity appeared to affect other-cause, but not PCa-specific, mortality after accounting for patient and tumour characteristics, and treatment type. Increasing comorbidity did not impact on PCa-specific mortality irrespective of radical treatment (RP or RT). Consequently, in population-based comparative PCa treatment effectiveness studies, the differences in oncological outcomes may not be due to the varying distribution of comorbidity among treatment groups, hence comorbidity is unlikely to be a confounder.
Source of Funding: None; PcBaSe Sweden is funded by the Swedish Research Council (25-2012-5047).
PD03-12 PROSTATE CANCER INCIDENCE STRATIFIED BY RACE AND GLEASON SCORE: A SEER DATABASE ANALYSIS OF THE USPSTF GUIDELINE ERA
Daniel Au*, Johar Syed, Sameer Siddiqui, Saint Louis, MO INTRODUCTION AND OBJECTIVES: In 2008 and extended in 2012, the US Preventive Services Task Force (USPSTF) issued guidelines stating there was insufficient evidence to support prostate cancer screening. Using the Surveillance Epidemiology and End Result (SEER) database, we sought to determine the effect of recent USPSTF recommendations on prostate cancer incidence based on Gleason score (GS), and to identify differences in GS based on race.
METHODS: SEER database was analyzed from 2008-2013. Patients were divided based on recorded race. GS were stratified as low (2-6), intermediate (7) or high (8-10). Incidence was compared between 2008 and 2013 by determining incidence rate ratio (IRR) and annual percentage change (APC). Statistical analysis was performed with SEERSTAT and excel, confidence interval was set at 95%, with p< 0.05 as significant. RESULTS: 337,504 patients diagnosed with prostate cancer within SEER 18 between 2008 and 2013 were included in the analysis. The mean age range was between 65-74 years. Majority (68.1%) of patients were White, followed by 14.6% Black. GS 2-6 was recorded for 41.8%, followed by GS 7 in 36.2% of patients, and GS 8-10 in 15.9% of patients. Cumulative six year GS 2-6 incidence was noted to be 76.2, 52.9, 44.7 and 25.0 per 100,000 for Black (B), White (W), Hispanic (H), and Asian/Pacific Islanders (API), respectively. GS 7 incidences were 81.3, 46.4, 36.2 and 23.4 per 100,000 for B, W, H, and API, respectively. GS 8-10 was reported in 37.5, 21.0, 21.7 and 18.0 per 100,000 for B, W, H, and API, respectively. The IRR demonstrated a decline in incidence across races and Gleason scores. Between 2008 and 2013 GS 7 IRRs were 0.74 B, 0.65 W, 0.61 H, 0.60 API and GS 8-10 IRRs were 0.85 B, 0.89 W, 0.83 H, 0.78 API. APC significantly declined among all races for GS [2] [3] [4] [5] [6] and GS 7 . Additionally, APC significantly declined for B and H GS 8-10 (-3.51 B, -4.39 H). APC of GS 8-10 incidence showed no statistically significant increase or decline for W and API (-2.28 W, -5.05 API).
CONCLUSIONS: Analysis of SEER demonstrates a decline in incidence of prostate cancer among all races. Notably, there was a decline in GS 8-10 prostate cancer incidence for B, W, H, and API groups, suggesting reduced diagnosis of aggressive prostate cancer in the USPSTF guideline era.
